Human Genome (HGSI) Announces $400M Convertible Senior Notes Offering

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of its Convertible Senior Notes due 2018. The notes will be convertible, under certain circumstances, into cash, shares of the company’s common stock, or a combination, at the company’s election. The interest rate, conversion price and certain other terms of the offering are to be determined at the time of pricing. The company intends to grant the underwriter an option to purchase up to an additional $60 million aggregate principal amount of notes.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Solowin Holdings marks 10 years, expands into stablecoins and AI
• Home Depot expands executive roles, grants $500K in restricted stock